Human papillomavirus genotyping using an automated film-based chip array

Journal of Molecular Diagnostics

Volumn 11, Issue 5, 2009, Pages 439-445

  Erali, Maria ^a,c   Pattison, David C ^a   Wittwer, Carl T ^a,b   Petti, Cathy A ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOMATION; DEVICE; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UTERINE CERVIX CYTOLOGY; VIRUS TYPING; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

GENOTYPE; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION;

EID: 70249147695     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.080154     Document Type: Article

References (16)

1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632 (Pubitemid 46986496)
2. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific hpv testing in clinical practice. J Nat Cancer Inst 2005, 97:1072-1079 (Pubitemid 41417924)
3. Castle PE, Solomon D, Schiffman M, Wheeler CM: Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Nat Cancer Inst 2005, 97:1066-1071 (Pubitemid 41417923)
4. Wallin K-L, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999, 341:1633-1638
5. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1157-1164 (Pubitemid 40656461)
6. Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ: Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006, 15:1268-1273 (Pubitemid 44125280)
7. Bulkmans NW, Bleeker MC, Berkhof J, Voorhorst FJ, Snijders PJ, Meijer CJ: Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005, 117:177-181 (Pubitemid 41377435)
8. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73 (Pubitemid 36241220)
9. Castle PE: Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol 2008, 168:138-144
10. Kjaer SK, van den Brule AJC, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002, 325:572-579 (Pubitemid 35026129)
11. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS: Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:123-137 (Pubitemid 351951589)
12. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, Burk RD: PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997, 35:1304-1310 (Pubitemid 27216785)
13. Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Wacholder S, Burk RD, Manos MM, Schussler JE, Macomber P, Schiffman M: Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus dna assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol 2003, 41:4022-4030 (Pubitemid 37099659)
14. Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A: Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002, 11:1394-1399 (Pubitemid 35340375)
15. Yee C, Krishnan-Hewlett I, Baker C, Schlegel R, Howley P: Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 1985, 119:361-363 (Pubitemid 15051884)
16. Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K, Snijders P, Peto J, Meijer C, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19 (Pubitemid 29406813)